SCHEMBL3528003

SCHEMBL3528003

COC(=O)COc1ccc(C(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLA2G4B P0C869 7/20 0.62
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
NPC1 O15118 1/20 0.56
POLB P06746 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
PTGS2 P35354 1/20 0.55
PKM P14618 1/20 0.55
TSHR P16473 2/20 0.54
MAPK1 P28482 2/20 0.54
USP2 O75604 1/20 0.54
ALOX15 P16050 1/20 0.54
HSD17B10 Q99714 1/20 0.54
SRD5A2 P31213 1/20 0.54
PLA2G4A P47712 1/20 0.54
MAPT P10636 1/20 0.54
TP53 P04637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7429537 0.92 PLA2G4B (0.54) PLA2G4BCA1CA2NPC1POLB
SCHEMBL2116437 0.88 PTGS2 (0.66) POLBSMN1; SMN2PTGS2HSD17B10MAPT
SCHEMBL10299626 0.87 PTGS2 (0.57) NPC1POLBRAB9ASMN1; SMN2PTGS2
SCHEMBL6960461 0.85 L3MBTL1 (0.61) POLBRAB9APTGS2MAPT
SCHEMBL4262664 0.85 MAPT (0.70) CA1CA2NPC1POLBRAB9A
SCHEMBL10080489 0.85 KDM4E (0.63) PLA2G4BSMN1; SMN2PTGS2HSD17B10
SCHEMBL9327172 0.85 PLA2G4B (0.61) PLA2G4BPKMTSHRMAPK1SRD5A2
SCHEMBL2386974 0.84 SMN1; SMN2 (0.60) NPC1POLBRAB9ASMN1; SMN2MAPK1
SCHEMBL28123483 0.84 MAPT (0.60) NPC1POLBRAB9ASMN1; SMN2PTGS2
SCHEMBL7283346 0.84 PTGS2 (0.58) NPC1POLBRAB9ASMN1; SMN2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436201-B2 Functionalized diphenolics and absorbable polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2013-05-07 US disclosed
EP-1523473-B1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2013-02-27 EP disclosed
US-20130041045-A1 FUNCTIONALIZED DIPHENOLICS AND ABSORBABLE POLYMERS THEREFROM BEZWADA BIOMEDICAL, LLC (US) 2013-02-14 US disclosed
US-8288505-B2 Functionalized diphenolics and absorbable polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2012-10-16 US disclosed
US-7858616-B2 Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-12-28 US disclosed
US-20090197876-A1 INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-08-06 US disclosed
US-7560480-B2 Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-14 US disclosed
US-7547703-B2 Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-06-16 US disclosed
US-20090118318-A1 Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases ASTRAZENECA AB (SE) 2009-05-07 US disclosed
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-5612373-A ANTICOAGULANTS ZENECA LIMITED (GB) 1997-03-18 US disclosed
WO-1995000472-A1 1,2 DIACYLATED HYDRAZINE DERIVATIVES AND THEIR USE AS ALL ADHESION INHIBITORS ZENECA LIMITED (GB) 1995-01-05 WO disclosed
EP-0632016-A1 1,2-Diacylated hydrazine derivatives and their use as cell adhesion inhibitors ZENECA LIMITED (GB) 1995-01-04 EP disclosed
EP-0368912-B1 POLYANHYDRIDES WITH IMPROVED HYDROLYTIC DEGRADATION PROPERTIES MASSACHUSETTS INST TECHNOLOGY (US) 1994-03-16 EP disclosed
US-5254576-A Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1993-10-19 US disclosed
EP-0368912-A4 POLYANHYDRIDES WITH IMPROVED HYDROLYTIC DEGRADATION PROPERTIES 1990-12-19 EP disclosed
EP-0368912-A1 POLYANHYDRIDES WITH IMPROVED HYDROLYTIC DEGRADATION PROPERTIES. MASSACHUSETTS INST TECHNOLOGY (US) 1990-05-23 EP disclosed
US-4857311-A FROM P-CARBOXYPHEN(-OXY OR -YL)ALKANOIC ACID; BIODEGRADABLE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1989-08-15 US disclosed
WO-1989000855-A1 POLYANHYDRIDES WITH IMPROVED HYDROLYTIC DEGRADATION PROPERTIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1989-02-09 WO disclosed
US-4105790-A ANTICOAGULANTS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1978-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130041045-A1 FUNCTIONALIZED DIPHENOLICS AND ABSORBABLE POLYMERS THEREFROM DDT, DHCR7, NOTUM PLA2G4B 1802/4885CA1 2199/4885CA2 2543/4885
US-20090118318-A1 Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases CCR8, CCR1, CCR10 PLA2G4B 1397/4885CA1 4546/4885CA2 3858/4885
US-20090197876-A1 INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS KDR, FLT1, ERBB2 PLA2G4B 2817/4885CA1 4473/4885CA2 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.